Terumo Heart names new president and CEO

Most recently, Mr Pinon was CEO of Bioheart, a biotechnology company focused on the development of heart failure therapies and devices. Prior to Bioheart, Mr Pinon held a variety of positions with Johnson & Johnson including worldwide vice president of sales and marketing at Cordis.

Chisato Nojiri will continue to serve as chairperson of the board and chief medical officer of Terumo Heart. Dr Nojiri has been instrumental in bringing the product from its very early development phase through commercialization in Europe, to the start of the US pivotal clinical trial and recent completion of the Japanese clinical trial patient enrollment. Dr Nojiri will continue her global clinical and scientific focus and leadership.

Dr Nojiri said: “With the expansion of our US clinical sites, Terumo Heart is experiencing rapid growth. Mr Pinon’s proven track record in the cardiovascular industry and extensive sales and operational experience, are ideally suited to lead our commercialization efforts in the US and continued growth in Europe.”